迈得医疗(688310) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥64,235,359.54, representing a decrease of 0.09% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥8,714,789.59, down 43.99% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,874,601.72, a decline of 65.26% compared to the previous year[5] - The net profit attributable to shareholders for the year-to-date period was ¥19,287,694.66, down 50.89% year-over-year[5] - Net profit for the third quarter of 2022 was ¥19,924,085.82, a decrease from ¥38,823,970.51 in the same quarter of 2021, reflecting a decline of approximately 48.7%[21] - The total comprehensive income for Q3 2022 was CNY 20,053,137.13, compared to CNY 39,139,532.56 in Q3 2021, reflecting a decrease of approximately 48.8%[22] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.23, down from CNY 0.47 in Q3 2021, representing a decline of 51.1%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥983,424,301.28, an increase of 11.84% from the end of the previous year[6] - The company's total assets as of the end of the third quarter of 2022 amounted to ¥983,424,301.28, compared to ¥879,311,660.19 at the end of the same period in 2021, showing an increase of about 11.85%[19] - Total liabilities increased to ¥217,211,868.47 in the third quarter of 2022 from ¥116,670,640.13 in the same quarter of 2021, marking an increase of approximately 86.1%[18] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥40,175,806.98, reflecting an increase of 83.26% compared to the previous year[6] - Net cash flow from operating activities for the first three quarters of 2022 was CNY 40,175,806.98, an increase of 83.2% compared to CNY 21,922,778.27 in the same period of 2021[26] - The net increase in cash and cash equivalents for Q3 2022 was -CNY 28,669,436.43, compared to -CNY 95,113,060.16 in Q3 2021, indicating an improvement in cash flow management[27] - The cash and cash equivalents balance at the end of Q3 2022 was CNY 286,172,215.95, down from CNY 330,348,840.49 at the end of Q3 2021[27] Research and Development - Research and development expenses for Q3 2022 amounted to ¥8,290,060.01, a decrease of 11.90% year-over-year[6] - Research and development expenses for the first three quarters of 2022 were ¥26,912,034.42, up from ¥22,330,472.31 in 2021, indicating an increase of approximately 20.4%[20] Shareholder Information - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.83% of the total shares, indicating a strong control over the company[12] - The second-largest shareholder, Chen Wanshun, owns 12,630,000 shares, accounting for 15.11% of the total shares[12] - The company’s total number of ordinary shares outstanding at the end of the reporting period was 3,997,000[12] Strategic Initiatives - The company is actively engaging in market expansion and product development as part of its strategic initiatives[14] - The company has approved the grant of reserved restricted stock to incentive objects as part of its stock incentive plan, indicating a focus on employee retention and motivation[14] - The company has initiated a stock incentive plan adjustment, which may impact future stock performance and employee engagement[15] - The company has not reported any significant changes in its debt structure or major acquisitions during the reporting period[14] Other Financial Metrics - Basic earnings per share for Q3 2022 were ¥0.10, down 47.37% from the same period last year[6] - The weighted average return on equity was 1.15%, a decrease of 0.99 percentage points compared to the previous year[6] - The company reported a total of ¥3,840,187.87 in non-recurring gains for the current period[10] - Accounts receivable increased to ¥123,151,856.49 from ¥115,080,615.46, reflecting a growth of about 7.5% year-over-year[16] - The company’s financing receivables rose significantly to ¥49,868,651.46 from ¥16,603,117.44, marking an increase of approximately 200%[16] - The company reported a decrease in tax refunds received, amounting to CNY 8,901,480.61 in Q3 2022, down from CNY 12,499,434.35 in Q3 2021[26]